Risk that the therapeutic efficacy of umbilical cord blood will not be confirmed
First written in FY2021. 4 of 5 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「At the same time, new issues may arise during the research process, and reviews related to clinical use may be prolonged, causing progress to fall short of expectations. Efficacy assessments may also take longer, or efficacy may not become clear.」
While disclosing progress in clinical research and confirmation of some effects, the company continues to explicitly identify the risks of prolonged reviews and efficacy assessments and failure to confirm therapeutic effects. - FY2025RestatedAnnual report
「If the clinical research fails to progress as anticipated or efficacy is not validated in the research, or if other new treatments emerge, the number of individuals storing umbilical cord blood with the company may decline.」
The company continues to address the risk of a decline in the number of people storing umbilical cord blood due to prolonged clinical research, failure to validate efficacy, or the emergence of alternative treatments, by pursuing clinical application with academic partners. - FY2023RestatedAnnual report
「The company considers the likelihood of this risk materializing to be low and forecasts that it would occur only in the long term. If it were to materialize, it could have a material impact on business performance and financial condition and could make it difficult for the company to continue operating.」
The company continues to address the risk that unvalidated therapeutic efficacy, prolonged research, or the emergence of other treatments could reduce the number of people storing umbilical cord blood, by pursuing clinical application with academic partners. - FY2022RestatedAnnual report
「Clinical research on umbilical cord blood in the field of regenerative medicine has only recently begun, and its efficacy and therapeutic effects have not been sufficiently validated. If the clinical research fails to progress as anticipated or efficacy is not validated in the research, or if other new treatments emerge, the number of individuals storing umbilical cord blood with the company may decline.」
The company continues to disclose the risk that prolonged clinical research, failure to validate efficacy, or the emergence of alternative treatments could reduce the number of people storing umbilical cord blood, along with its response of pursuing clinical application with academic partners. - FY2021First statedAnnual report
「Clinical research on umbilical cord blood in the field of regenerative medicine has only recently begun, and its efficacy and therapeutic effects have not been sufficiently validated. During the clinical research process, progress may fail to proceed as anticipated, including because the research may be prolonged, and its efficacy may not be clearly confirmed.」
As a countermeasure, the company states that it will set diseases for which no established treatment exists as development targets and pursue clinical application with academic partners.